Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Published:2021-09-01 Issue:9 Volume:157 Page:1047
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Blauvelt Andrew¹,Teixeira Henrique D.²,Simpson Eric L.³,Costanzo Antonio⁴⁵,De Bruin-Weller Marjolein⁶,Barbarot Sebastien⁷,Prajapati Vimal H.⁸⁹¹⁰¹¹¹²,Lio Peter¹³¹⁴,Hu Xiaofei²,Wu Tianshuang²,Liu John²,Ladizinski Barry²,Chu Alvina D.²,Eyerich Kilian¹⁵¹⁶

Affiliation:

1. Oregon Medical Research Center, Portland

2. AbbVie Inc, North Chicago, Illinois

3. Department of Dermatology, Oregon Health & Science University, Portland

4. Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy

5. Humanitas Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare, Rozzano, Italy

6. Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands

7. Department of Dermatology, Nantes Université, Centre Hospitalier Universitaire de Nantes, Nantes, France

8. Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

9. Division of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada

10. Division of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada

11. Skin Health & Wellness Centre, Calgary, Alberta, Canada

12. Dermatology Research Institute, Calgary, Alberta, Canada

13. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

14. Medical Dermatology Associates of Chicago, Chicago, Illinois

15. Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

16. Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2782803/jamadermatology_blauvelt_2021_oi_210044_1639151709.9087.pdf

Reference20 articles.

1. Atopic dermatitis.;Weidinger;Nat Rev Dis Primers,2018

2. Atopic dermatitis.;Langan;Lancet,2020

3. Targeting the Janus kinase family in autoimmune skin diseases.;Howell;Front Immunol,2019

4. JAK inhibitors for atopic dermatitis: an update.;He;Am J Clin Dermatol,2019

5. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.;Simpson;N Engl J Med,2016

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China;Journal of Medical Economics;2024-09-13

2. Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review;JAAD International;2024-09

3. Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-30

4. Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates;Dermatology and Therapy;2024-08-22

5. Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China;Dermatitis®;2024-08-20